logo
logo
VNDA stock ticker logo

Vanda Pharmaceuticals Inc.

NASDAQ•VNDA
CEO: Dr. Mihael H. Polymeropoulos M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 2006-04-12
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
連絡先情報
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC, 20037, United States
202-734-3400
www.vandapharma.com
時価総額
$549.11M
PER (TTM)
-2.5
17.5
配当利回り
--
52週高値
$9.94
52週安値
$3.81
52週レンジ
89%
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$57.22M+0.00%
直近4四半期の推移

EPS

-$2.39+0.00%
直近4四半期の推移

フリーCF

-$29.52M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Fanapt Sales Surge Fanapt net product sales reached $117.3M, showing 24% growth versus prior year results for 2025.
Total Revenue Growth Total net product sales grew 9% to $216.1M for fiscal year 2025, despite HETLIOZ sales decline.
NEREUS Regulatory Approval NEREUS received FDA approval in December 2025 for preventing vomiting induced by motion in adults.
Strong Cash Position Maintained $263.8M in total cash and marketable securities at year-end 2025, supporting operations.

リスク要因

HETLIOZ Generic Competition HETLIOZ net sales declined 7% to $71.4M due to generic competition and elevated specialty pharmacy inventory levels.
Significant Operating Losses Significant operating losses continued, resulting in a net loss of $(220.5M) for the fiscal year 2025.
R&D and SG&A Spending R&D expenses rose 47% to $109.3M and SG&A increased 63% due to commercial investments.
Pipeline Approval Uncertainty Future commercial success hinges on obtaining regulatory approvals for pipeline candidates like Bysanti and Imsidolimab.

見通し

Bysanti FDA Decision Pending Bysanti NDA for bipolar I/schizophrenia under FDA review; decision expected February 21, 2026 PDUFA date.
Advancing Key Pipeline Studies Submitted Imsidolimab BLA for GPP in Q4 2025; Phase III studies ongoing for VQW-765 and Bysanti MDD.
NEREUS Phase III Planning Anticipate initiating Phase III program for NEREUS in GLP-1 induced nausea/vomiting in the first half of 2026.
Continued Commercial Investment Maintain strategic investments in commercial infrastructure supporting Fanapt and future product launches.

同業比較

売上高 (TTM)

VNDA stock ticker logoVNDA
$216.11M
+8.7%
ARCT stock ticker logoARCT
$74.12M
-46.4%
SCPH stock ticker logoSCPH
$49.97M
+107.8%

粗利益率 (最新四半期)

ACIU stock ticker logoACIU
100.0%
+0.0pp
VNDA stock ticker logoVNDA
93.3%
+0.1pp
VYGR stock ticker logoVYGR
93.2%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CAPR$1.53B-18.6-71.0%11.5%
ALLO$555.08M-2.9-57.1%18.0%
VNDA$549.11M-2.5-49.2%2.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし